DRW Securities LLC Sells 589 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DRW Securities LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 72.0% during the second quarter, Holdings Channel reports. The institutional investor owned 229 shares of the biopharmaceutical company’s stock after selling 589 shares during the quarter. DRW Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $241,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $339,594,000. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. First Trust Advisors LP boosted its position in shares of Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the period. Finally, TD Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after purchasing an additional 166,998 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock worth $10,695,833 in the last 90 days. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on REGN shares. Royal Bank of Canada reduced their target price on Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a report on Tuesday. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,118.62.

Regeneron Pharmaceuticals Trading Down 4.2 %

Shares of NASDAQ:REGN opened at $1,045.98 on Wednesday. The company’s 50-day moving average price is $1,130.96 and its two-hundred day moving average price is $1,034.01. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market capitalization of $115.31 billion, a PE ratio of 30.90, a price-to-earnings-growth ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $8.79 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.